Broadcast Date: 
  • Time: 

Successful development of advanced biotherapeutics relies on extensive characterization and tight quality control of protein interactions. Characterizing the binding properties of complex biomolecules, such as bispecific antibodies or reengineered probiotics, is a critical step. Biophysical data combined with functional assays are needed to predict efficacy and potency, optimize drug delivery, assess critical quality attributes, and improve biologics drug design. Traditional approaches have limited use in a complex biological environment with multiple interactions.

In this GEN webinar, our distinguished speakers will address these challenges, as they have developed and implemented a new dual-target and payload protein binding assay using AlphaPlex® technology, respectively. Our presenters will also discuss the latest technology to engineer bispecific antibody therapeutics against dual targets based on the molecular interactions known to contribute to overall disease state, as well as accurately dissect the affinities of both target binding domains directly and simultaneously in a matrixed cellular environment. Moreover, we will learn about the development of a custom assay to determine the level of binding activity between a payload protein and a therapeutic target to screen a small library of hits for improved activity, in addition to hearing about innovative technology to optimize drug delivery using an engineered probiotic-protein delivery system.


A live Q&A followed the presentation, offering a chance to pose questions to our expert panelists.

Elizabeth Christian
Elizabeth Christian
Senior Scientist
Devon Stork
Devon Stork, PhD
Principal Scientist

Perkin Elmer logo